Analysis of secretion profiles of pro-angiogenic paracrine factors in clinical trials of stem cell therapy for myocardial infarction
Lichtenauer, M; Anker, A; Wernly, B; Leisch, M; Schreiber, C; Arrer, A; Wodnar, R; Jung, C; Hoppe, UC EUR HEART J. 2015; 36: 611-611.
PGDFR blockade as a novel therapy for NPM-ALK(+) anaplastic large cell lymphoma
Kenner, L; Kuroll, M; Hartmann, T; Krenn, P; Schlederer, M; Prutsch, N; Greil, R; Turner, S; Merkel, O BRIT J HAEMATOL. 2015; 171: 28-28.
Lung Health in Lungau: Alveolitis, ARDS or else
Rudelstorfer, G; Lichtenschopf, A; Studnicka-Benke, A; Pretsch, I; Studnicka, M WIEN KLIN WOCHENSCHR. 2015; 127(19-20): 809-810.
Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
Karthaus, M; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Zhang, Y; Oliner, KS; Demonty, G; Kohne, CH EUR J CANCER. 2015; 51: S375-S376.
Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.
Singer, CF; Filipits, M; Jahn, S; Abete, L; Jakesz, R; Greil, R; Bauernhofer, T; Kwasny, W; Seifert, M; Fitzal, F; Schmitt, M; Moinfar, F; Gnant, M J CLIN ONCOL. 2015; 33(15):
Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.
Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Radisic, VB; Bergh, JCS; Fitzal, F; Egle, D; Mlineritsch, B; Steger, GG; Talbot, S; Warner, DJ; Fesl, C; Singer, CF J CLIN ONCOL. 2015; 33(15):
Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
Kohne, CH; Hofheinz, RD; Mineur, L; Letocha, H; Greil, R; Thaler, J; Twomey, B; Oliner, KS; Boedigheimer, M; Terwey, JH; Karthaus, M J CLIN ONCOL. 2015; 33(15):
DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial
Boige, V; Vincent, M; Alexandre, P; Stoehlmacher, J; Tejpar, S; Landolfi, S; Le Malicot, K; Greil, R; Cuyle, PJAR; Yilmaz, MKN; Faroux, R; Matzdorff, A; Salazar, R; Sanches, E; Mineur, L; Lepage, C; Taieb, J; Laurent-Puig, P J CLIN ONCOL. 2015; 33(15):
Pathological mechanisms underlying contracture formation in epidermolysis bullosa
Liemberger, B; Hainzl, S; Koller, U; Wally, V; Hofbauer, JP; Studnicka-Benke, A; Diem, A; Bauer, J; Breitenbach, J; Gruber, C J INVEST DERMATOL. 2015; 135: S59-S59.
Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
Kohne, CH; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Twomey, B; Oliner, KS; Boedigheimer, M; Terwey, JH; Karthaus, M J CLIN ONCOL. 2015; 33(3):